Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUIS ANDRES GARZA

Allopathic & Osteopathic Physicians Dermatology

NPI
1427074517
CMS profile
1172449
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$8,523.47

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,000.00 1
Travel and Lodging $319.00 1
Food and Beverage $204.47 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Almirall LLC $8,523.47 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUIS ANDRES GARZA

NPI 1427074517 · CMS profile ID 1172449

Allopathic & Osteopathic Physicians / Dermatology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427074517?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUIS ANDRES GARZA, NPI 1427074517, CMS profile ID 1172449. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427074517?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LUIS ANDRES GARZA, NPI 1427074517, CMS profile ID 1172449. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427074517?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LUIS ANDRES GARZA, NPI 1427074517, CMS profile ID 1172449, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1427074517?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $8,523.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Almirall LLC $8,000.0001/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676655377 CMS
Almirall LLC $319.0001/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676655383 CMS
Almirall LLC $204.4701/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676655387 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,523.47 3
PY2023 $20.71 1
PY2025 $35,673.51 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $221,062.00 220
PY2024 Principal investigator $230,576.67 271
PY2023 Principal investigator $37,517.27 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

271 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,353.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105558
Principal investigator 1 Incyte Corporation $2,274.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105560
Principal investigator 1 Incyte Corporation $183.90 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105562
Principal investigator 1 Incyte Corporation $2,262.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105564
Principal investigator 1 Incyte Corporation $3,248.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105566
Principal investigator 1 Incyte Corporation $2,131.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105624
Principal investigator 1 Incyte Corporation $2,262.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105626
Principal investigator 1 Incyte Corporation $2,810.00 12/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105674
Principal investigator 1 Incyte Corporation $1,231.00 12/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105526
Principal investigator 1 Incyte Corporation $1,340.00 12/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105528
Principal investigator 1 Incyte Corporation $145.00 12/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105530
Principal investigator 1 Incyte Corporation $154.00 12/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105532
Principal investigator 1 Incyte Corporation $310.00 12/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105534
Principal investigator 1 Incyte Corporation $1,474.00 12/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105536
Principal investigator 1 Incyte Corporation $64.70 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105598
Principal investigator 1 Incyte Corporation $54.80 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105600
Principal investigator 1 Incyte Corporation $68.70 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105602
Principal investigator 1 Incyte Corporation $59.10 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105604
Principal investigator 1 Incyte Corporation $135.40 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105606
Principal investigator 1 Incyte Corporation $14.80 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105608
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105610
Principal investigator 1 Incyte Corporation $12.40 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105612
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105614
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105616
Principal investigator 1 Incyte Corporation $62.30 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105666
Principal investigator 1 Incyte Corporation $49.40 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105696
Principal investigator 1 Incyte Corporation $49.30 12/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105732
Principal investigator 1 Incyte Corporation $2,353.00 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105538
Principal investigator 1 Incyte Corporation $3,248.00 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105540
Principal investigator 1 Incyte Corporation $2,274.00 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105542
Principal investigator 1 Incyte Corporation $2,274.00 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105640
Principal investigator 1 Incyte Corporation $2,131.00 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105644
Principal investigator 1 Incyte Corporation $2,131.00 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105646
Principal investigator 1 Incyte Corporation $476.80 11/06/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105684
Principal investigator 1 Incyte Corporation $91.60 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105588
Principal investigator 1 Incyte Corporation $1.60 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105590
Principal investigator 1 Incyte Corporation $19.40 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105592
Principal investigator 1 Incyte Corporation $270.80 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105594
Principal investigator 1 Incyte Corporation $41.10 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105596
Principal investigator 1 Incyte Corporation $41.10 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105628
Principal investigator 1 Incyte Corporation $41.10 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105630
Principal investigator 1 Incyte Corporation $41.10 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105632
Principal investigator 1 Incyte Corporation $123.40 11/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105748
Principal investigator 1 Incyte Corporation $1,340.00 10/16/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105550
Principal investigator 1 Incyte Corporation $300.00 10/16/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105552
Principal investigator 1 Incyte Corporation $154.00 10/16/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105554
Principal investigator 1 Incyte Corporation $1,231.00 10/16/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105556
Principal investigator 1 Incyte Corporation $2,353.00 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105544
Principal investigator 1 Incyte Corporation $2,262.00 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105546
Principal investigator 1 Incyte Corporation $568.70 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105548
Principal investigator 1 Incyte Corporation $2,131.00 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105618
Principal investigator 1 Incyte Corporation $2,353.00 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105620
Principal investigator 1 Incyte Corporation $2,262.00 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105622
Principal investigator 1 Incyte Corporation $2,131.00 10/11/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105720
Principal investigator 1 Incyte Corporation $1,340.00 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105568
Principal investigator 1 Incyte Corporation $530.00 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105570
Principal investigator 1 Incyte Corporation $1,231.00 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105572
Principal investigator 1 Incyte Corporation $1,474.00 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105574
Principal investigator 1 Incyte Corporation $462.00 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105576
Principal investigator 1 Incyte Corporation $123.40 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105578
Principal investigator 1 Incyte Corporation $135.40 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105580
Principal investigator 1 Incyte Corporation $12.20 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105582
Principal investigator 1 Incyte Corporation $1.60 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105584
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105586
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105634
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105636
Principal investigator 1 Incyte Corporation $41.10 10/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105638
Principal investigator 1 Incyte Corporation $2,274.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105240
Principal investigator 1 Incyte Corporation $3,270.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105400
Principal investigator 1 Incyte Corporation $453.50 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105418
Principal investigator 1 Incyte Corporation $340.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105424
Principal investigator 1 Incyte Corporation $4,020.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105426
Principal investigator 1 Incyte Corporation $670.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105428
Principal investigator 1 Incyte Corporation $154.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105430
Principal investigator 1 Incyte Corporation $296.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105440
Principal investigator 1 Incyte Corporation $2,262.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105500
Principal investigator 1 Incyte Corporation $2,353.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105510
Principal investigator 1 Incyte Corporation $3,270.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105512
Principal investigator 1 Incyte Corporation $162.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105642
Principal investigator 1 Incyte Corporation $290.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105664
Principal investigator 1 Incyte Corporation $2,262.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105730
Principal investigator 1 Incyte Corporation $2,353.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105770
Principal investigator 1 Incyte Corporation $2,262.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105772
Principal investigator 1 Incyte Corporation $3,248.00 09/18/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105774
Principal investigator 1 Incyte Corporation $97.08 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105454
Principal investigator 1 Incyte Corporation $62.27 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105458
Principal investigator 1 Incyte Corporation $19.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105460
Principal investigator 1 Incyte Corporation $2.48 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105462
Principal investigator 1 Incyte Corporation $406.20 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105464
Principal investigator 1 Incyte Corporation $194.65 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105466
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105484
Principal investigator 1 Incyte Corporation $41.10 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105486
Principal investigator 1 Incyte Corporation $41.10 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105490
Principal investigator 1 Incyte Corporation $41.10 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105496
Principal investigator 1 Incyte Corporation $41.10 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105498
Principal investigator 1 Incyte Corporation $19.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105518
Principal investigator 1 Incyte Corporation $19.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105520
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105522
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105524
Principal investigator 1 Incyte Corporation $16.44 09/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105734
Principal investigator 1 Incyte Corporation $3,270.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105408
Principal investigator 1 Incyte Corporation $3,248.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105410
Principal investigator 1 Incyte Corporation $2,131.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105412
Principal investigator 1 Incyte Corporation $3,121.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105420
Principal investigator 1 Incyte Corporation $2,353.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105422
Principal investigator 1 Incyte Corporation $2,131.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105492
Principal investigator 1 Incyte Corporation $871.60 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105494
Principal investigator 1 Incyte Corporation $2,131.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105502
Principal investigator 1 Incyte Corporation $2,131.00 08/14/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105710
Principal investigator 1 Incyte Corporation $135.40 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105236
Principal investigator 1 Incyte Corporation $19.44 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105456
Principal investigator 1 Incyte Corporation $2.79 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105470
Principal investigator 1 Incyte Corporation $48.60 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105472
Principal investigator 1 Incyte Corporation $68.70 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105474
Principal investigator 1 Incyte Corporation $49.36 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105476
Principal investigator 1 Incyte Corporation $54.76 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105478
Principal investigator 1 Incyte Corporation $59.13 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105480
Principal investigator 1 Incyte Corporation $80.90 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105482
Principal investigator 1 Incyte Corporation $113.26 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105488
Principal investigator 1 Incyte Corporation $32.88 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105516
Principal investigator 1 Incyte Corporation $62.27 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105672
Principal investigator 1 Incyte Corporation $123.40 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105688
Principal investigator 1 Incyte Corporation $32.88 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105690
Principal investigator 1 Incyte Corporation $32.88 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105692
Principal investigator 1 Incyte Corporation $32.88 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105694
Principal investigator 1 Incyte Corporation $1.55 08/01/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105700
Principal investigator 1 Incyte Corporation $704.00 07/24/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105414
Principal investigator 1 Incyte Corporation $308.00 07/24/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105416
Principal investigator 1 Incyte Corporation $2,345.00 07/24/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105468
Principal investigator 1 Incyte Corporation $430.00 07/24/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105650
Principal investigator 1 Incyte Corporation $185.00 07/24/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105652
Principal investigator 1 Incyte Corporation $1,474.00 07/24/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105718
Principal investigator 1 Incyte Corporation $2,274.00 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105398
Principal investigator 1 Incyte Corporation $3,270.00 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105402
Principal investigator 1 Incyte Corporation $2,353.00 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105404
Principal investigator 1 Incyte Corporation $2,262.00 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105406
Principal investigator 1 Incyte Corporation $549.30 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105504
Principal investigator 1 Incyte Corporation $2,353.00 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105506
Principal investigator 1 Incyte Corporation $2,353.00 07/10/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105508
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105432
Principal investigator 1 Incyte Corporation $4.86 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105434
Principal investigator 1 Incyte Corporation $2.43 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105436
Principal investigator 1 Incyte Corporation $4.03 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105438
Principal investigator 1 Incyte Corporation $48.60 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105442
Principal investigator 1 Incyte Corporation $270.80 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105444
Principal investigator 1 Incyte Corporation $148.85 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105446
Principal investigator 1 Incyte Corporation $80.90 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105448
Principal investigator 1 Incyte Corporation $21.87 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105450
Principal investigator 1 Incyte Corporation $98.72 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105452
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105514
Principal investigator 1 Incyte Corporation $41.10 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105654
Principal investigator 1 Incyte Corporation $41.10 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105656
Principal investigator 1 Incyte Corporation $41.10 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105658
Principal investigator 1 Incyte Corporation $41.10 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105660
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105752
Principal investigator 1 Incyte Corporation $16.44 07/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105754
Principal investigator 1 Incyte Corporation $737.00 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105354
Principal investigator 1 Incyte Corporation $7,386.00 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105356
Principal investigator 1 Incyte Corporation $310.00 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105362
Principal investigator 1 Incyte Corporation $770.00 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105364
Principal investigator 1 Incyte Corporation $648.56 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105372
Principal investigator 1 Incyte Corporation $3,216.00 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105378
Principal investigator 1 Incyte Corporation $5,360.00 06/19/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105668
Principal investigator 1 Incyte Corporation $3,121.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105342
Principal investigator 1 Incyte Corporation $2,262.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105344
Principal investigator 1 Incyte Corporation $3,270.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105350
Principal investigator 1 Incyte Corporation $3,248.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105358
Principal investigator 1 Incyte Corporation $2,131.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105360
Principal investigator 1 Incyte Corporation $3,270.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105388
Principal investigator 1 Incyte Corporation $3,121.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105390
Principal investigator 1 Incyte Corporation $2,262.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105396
Principal investigator 1 Incyte Corporation $2,353.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105686
Principal investigator 1 Incyte Corporation $127.10 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105722
Principal investigator 1 Incyte Corporation $3,121.00 06/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105724
Principal investigator 1 Incyte Corporation $124.54 06/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105380
Principal investigator 1 Incyte Corporation $135.40 06/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105382
Principal investigator 1 Incyte Corporation $3,270.00 05/03/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105234
Principal investigator 1 Incyte Corporation $1,564.50 05/03/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105352
Principal investigator 1 Incyte Corporation $2,262.00 05/03/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105698
Principal investigator 1 Incyte Corporation $45.80 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105366
Principal investigator 1 Incyte Corporation $0.31 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105368
Principal investigator 1 Incyte Corporation $135.40 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105370
Principal investigator 1 Incyte Corporation $62.27 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105384
Principal investigator 1 Incyte Corporation $270.80 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105386
Principal investigator 1 Incyte Corporation $62.27 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105392
Principal investigator 1 Incyte Corporation $270.80 05/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105394
Principal investigator 1 Incyte Corporation $1,472.60 04/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105346
Principal investigator 1 Incyte Corporation $2,384.00 04/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105348
Principal investigator 1 Incyte Corporation $3,248.00 04/05/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105716
Principal investigator 1 Incyte Corporation $123.40 04/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105374
Principal investigator 1 Incyte Corporation $80.90 04/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105376
Principal investigator 1 Incyte Corporation $22.90 04/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105648
Principal investigator 1 Incyte Corporation $2.48 04/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105768
Principal investigator 1 Incyte Corporation $3,121.00 03/13/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105242
Principal investigator 1 Incyte Corporation $2,131.00 03/13/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105298
Principal investigator 1 Incyte Corporation $2,353.00 03/13/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105302
Principal investigator 1 Incyte Corporation $3,270.00 03/13/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105304
Principal investigator 1 Incyte Corporation $3,121.00 03/13/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105308
Principal investigator 1 Incyte Corporation $1,543.40 03/13/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105706
Principal investigator 1 Incyte Corporation $0.62 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105244
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105264
Principal investigator 1 Incyte Corporation $49.36 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105274
Principal investigator 1 Incyte Corporation $74.04 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105290
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105312
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105330
Principal investigator 1 Incyte Corporation $45.80 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105670
Principal investigator 1 Incyte Corporation $7.29 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105750
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105766
Principal investigator 1 Incyte Corporation $3,121.00 02/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105300
Principal investigator 1 Incyte Corporation $2,404.70 02/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105306
Principal investigator 1 Incyte Corporation $2,262.00 02/07/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105702
Principal investigator 1 Incyte Corporation $45.80 02/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105272
Principal investigator 1 Incyte Corporation $64.72 02/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105280
Principal investigator 1 Incyte Corporation $2.48 02/02/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105704
Principal investigator 1 Incyte Corporation $2,616.00 01/08/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105332
Principal investigator 1 Incyte Corporation $3,270.00 01/08/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105662
Principal investigator 1 Incyte Corporation $123.40 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105238
Principal investigator 1 Incyte Corporation $2.17 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105246
Principal investigator 1 Incyte Corporation $4.86 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105248
Principal investigator 1 Incyte Corporation $8.22 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105250
Principal investigator 1 Incyte Corporation $3.10 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105252
Principal investigator 1 Incyte Corporation $7.29 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105254
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105256
Principal investigator 1 Incyte Corporation $14.58 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105258
Principal investigator 1 Incyte Corporation $19.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105260
Principal investigator 1 Incyte Corporation $24.68 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105262
Principal investigator 1 Incyte Corporation $49.36 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105266
Principal investigator 1 Incyte Corporation $48.60 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105268
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105270
Principal investigator 1 Incyte Corporation $54.76 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105276
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105278
Principal investigator 1 Incyte Corporation $68.70 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105282
Principal investigator 1 Incyte Corporation $64.72 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105284
Principal investigator 1 Incyte Corporation $118.26 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105286
Principal investigator 1 Incyte Corporation $135.40 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105288
Principal investigator 1 Incyte Corporation $129.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105292
Principal investigator 1 Incyte Corporation $148.08 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105294
Principal investigator 1 Incyte Corporation $270.80 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105296
Principal investigator 1 Incyte Corporation $14.58 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105310
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105314
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105316
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105318
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105320
Principal investigator 1 Incyte Corporation $54.76 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105322
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105324
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105326
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105328
Principal investigator 1 Incyte Corporation $148.08 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105334
Principal investigator 1 Incyte Corporation $8.22 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105336
Principal investigator 1 Incyte Corporation $8.22 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105338
Principal investigator 1 Incyte Corporation $8.22 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105340
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105676
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105678
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105680
Principal investigator 1 Incyte Corporation $41.10 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105682
Principal investigator 1 Incyte Corporation $59.13 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105708
Principal investigator 1 Incyte Corporation $49.36 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105712
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105714
Principal investigator 1 Incyte Corporation $80.90 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105726
Principal investigator 1 Incyte Corporation $34.35 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105728
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105736
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105738
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105740
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105742
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105744
Principal investigator 1 Incyte Corporation $16.44 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105746
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105756
Principal investigator 1 Incyte Corporation $49.32 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105758
Principal investigator 1 Incyte Corporation $2.43 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105760
Principal investigator 1 Incyte Corporation $0.62 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105762
Principal investigator 1 Incyte Corporation $2.48 01/04/2024 Non-covered Recipient Entity
JOHN HOPKINS UNIVERSITY-SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1155105764